Comparative Pharmacology
Head-to-head clinical analysis: CHEWTADZY versus TADALAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHEWTADZY versus TADALAFIL.
CHEWTADZY vs TADALAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.
Inhibitor of phosphodiesterase type 5 (PDE5), enhancing cyclic guanosine monophosphate (cGMP)-mediated relaxation of smooth muscle in the corpus cavernosum and pulmonary vasculature.
2 mg orally twice daily
Erectile dysfunction: 10-20 mg orally as needed, 30-60 minutes before sexual activity; maximum 1 dose per day. Benign prostatic hyperplasia: 5 mg orally once daily. Pulmonary arterial hypertension: 40 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateTadalafil + Torasemide
"Tadalafil may increase the antihypertensive activities of Torasemide."
Clinical Note
moderateTadalafil + Travoprost
"Tadalafil may increase the antihypertensive activities of Travoprost."
Clinical Note
moderateTadalafil + Unoprostone
"Tadalafil may increase the antihypertensive activities of Unoprostone."
Clinical Note
moderateTadalafil + Hydrochlorothiazide
"Tadalafil may increase the antihypertensive activities of Hydrochlorothiazide."
Terminal elimination half-life 12-15 hours, allowing once-daily dosing; prolonged in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 17.5 hours in healthy subjects; supports once-daily dosing and prolonged effect (up to 36 hours for erectile function).
Primarily renal (55-65% unchanged), biliary/fecal (20-30%), with minor metabolism (<10%)
Primarily hepatic metabolism (CYP3A4); 36% excreted in urine (mainly metabolites), 61% in feces (mainly metabolites), <0.1% unchanged in urine.
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor